Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.
Mingshan SunShijie LiZhenyi LiuSai MaXiaohan LiuQing MengYueyue ZhengChunyan ChenPublished in: Leukemia research (2024)
Flumatinib demonstrates favorable efficacy and safety. Treatment discontinuation can result in a poorer molecular response and long-term prognosis.